Qiang Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6636266/publications.pdf

Version: 2024-02-01

215 papers

12,578 citations

64 h-index 101 g-index

222 all docs 222 docs citations

times ranked

222

16607 citing authors

#	Article	IF	CITATIONS
1	One-pot preparation of nanodispersion with readily available components for localized tumor photothermal and photodynamic therapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 120-128.	9.1	4
2	A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination. Nano Letters, 2022, 22, 2978-2987.	9.1	33
3	Dissecting extracellular and intracellular distribution of nanoparticles and their contribution to therapeutic response by monochromatic ratiometric imaging. Nature Communications, 2022, 13, 2004.	12.8	13
4	Nanoparticulates reduce tumor cell migration through affinity interactions with extracellular migrasomes and retraction fibers. Nanoscale Horizons, 2022, 7, 779-789.	8.0	7
5	A pyroptosis nanotuner for cancer therapy. Nature Nanotechnology, 2022, 17, 788-798.	31.5	84
6	The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems. Acta Pharmaceutica Sinica B, 2021, 11, 961-977.	12.0	29
7	Enhanced oral absorption and anti-inflammatory activity of ellagic acid via a novel type of case in nanosheets constructed by simple coacervation. International Journal of Pharmaceutics, 2021, 594, 120131.	5 . 2	4
8	Sequential Modulations of Tumor Vasculature and Stromal Barriers Augment the Active Targeting Efficacy of Antibodyâ€Modified Nanophotosensitizer in Desmoplastic Ovarian Carcinoma. Advanced Science, 2021, 8, 2002253.	11.2	21
9	Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy. Nature Communications, 2021, 12, 2385.	12.8	25
10	Boosting innate and adaptive antitumor immunity via a biocompatible and carrier-free nanovaccine engineered by the bisphosphonates-metal coordination. Nano Today, 2021, 37, 101097.	11.9	11
11	Precise Monitoring of Singlet Oxygen in Specific Endocytic Organelles by Super-pH-Resolved Nanosensors. ACS Applied Materials & Samp; Interfaces, 2021, 13, 18533-18544.	8.0	20
12	Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy. Nano Letters, 2021, 21, 4371-4380.	9.1	39
13	Tumor Associated Macrophages and TAMsâ€Based Antiâ€Tumor Nanomedicines. Advanced Healthcare Materials, 2021, 10, e2100590.	7.6	33
14	A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives. Acta Pharmaceutica Sinica B, 2021, 11, 2396-2415.	12.0	55
15	Nanoprotein Interaction Atlas Reveals the Transport Pathway of Gold Nanoparticles across Epithelium and Its Association with Wnt/β-Catenin Signaling. ACS Nano, 2021, 15, 17977-17997.	14.6	19
16	A common strategy to improve transmembrane transport in polarized epithelial cells based on sorting signals: Guiding nanocarriers to TGN rather than to the basolateral plasma membrane directly. Journal of Controlled Release, 2021, 339, 430-444.	9.9	5
17	Proteomic analysis of intracellular protein corona of nanoparticles elucidates nano-trafficking network and nano-bio interactions. Theranostics, 2020, 10, 1213-1229.	10.0	48
18	A magnetism/laser-auxiliary cascaded drug delivery to pulmonary carcinoma. Acta Pharmaceutica Sinica B, 2020, 10, 1549-1562.	12.0	5

#	Article	IF	CITATIONS
19	Thiolated Nanoparticles Overcome the Mucus Barrier and Epithelial Barrier for Oral Delivery of Insulin. Molecular Pharmaceutics, 2020, 17, 239-250.	4.6	33
20	Selfâ€Reporting Gold Nanourchins for Tumorâ€Targeted Chemoâ€Photothermal Therapy Integrated with Multimodal Imaging. Advanced Therapeutics, 2020, 3, 2000114.	3.2	6
21	Dual-targeting nanovesicles enhance specificity to dynamic tumor cells inÂvitro and inÂvivo via manipulation of $\hat{l}\pm v\hat{l}^2$ 3-ligand binding. Acta Pharmaceutica Sinica B, 2020, 10, 2183-2197.	12.0	14
22	pH/Cathepsin B Hierarchicalâ€Responsive Nanoconjugates for Enhanced Tumor Penetration and Chemoâ€Immunotherapy. Advanced Functional Materials, 2020, 30, 2003757.	14.9	57
23	Regulating Interactions Between Targeted Nanocarriers and Mononuclear Phagocyte System via an Esomeprazole-Based Preconditioning Strategy. International Journal of Nanomedicine, 2020, Volume 15, 6385-6399.	6.7	9
24	Strengthened Tumor Photodynamic Therapy Based on a Visible Nanoscale Covalent Organic Polymer Engineered by Microwave Assisted Synthesis. Advanced Functional Materials, 2020, 30, 2004834.	14.9	27
25	A combined "eat me/don't eat me―strategy based on extracellular vesicles for anticancer nanomedicine. Journal of Extracellular Vesicles, 2020, 9, 1806444.	12.2	121
26	Platelet membrane-cloaked paclitaxel-nanocrystals augment postoperative chemotherapeutical efficacy. Journal of Controlled Release, 2020, 324, 341-353.	9.9	41
27	The Endocytic Mechanism and Cytotoxicity of Boron-Containing Vesicles. Chemical and Pharmaceutical Bulletin, 2020, 68, 618-627.	1.3	10
28	Microfluidic-Based Holonomic Constraints of siRNA in the Kernel of Lipid/Polymer Hybrid Nanoassemblies for Improving Stable and Safe In Vivo Delivery. ACS Applied Materials & Delivery. ACS Applied Materials & Delivery. 14839-14854.	8.0	32
29	Anisotropic active ligandations in siRNA-Loaded hybrid nanodiscs lead to distinct carcinostatic outcomes by regulating nano-bio interactions. Biomaterials, 2020, 251, 120008.	11.4	17
30	A multiaspect study on transcytosis mechanism of sorafenib nanogranules engineered by high-gravity antisolvent precipitation. Journal of Controlled Release, 2020, 323, 600-612.	9.9	15
31	Glutathione-Priming Nanoreactors Enable Fluorophore Core/Shell Transition for Precision Cancer Imaging. ACS Applied Materials & Samp; Interfaces, 2019, 11, 33667-33675.	8.0	5
32	Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer. Acta Pharmaceutica Sinica B, 2019, 9, 1061-1077.	12.0	23
33	A Lipid Micellar System Loaded with Dexamethasone Palmitate Alleviates Rheumatoid Arthritis. AAPS PharmSciTech, 2019, 20, 316.	3.3	11
34	Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Nano Letters, 2019, 19, 6964-6976.	9.1	131
35	Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation. International Journal of Pharmaceutics, 2019, 559, 48-57.	5.2	10
36	Transferrin Functionization Elevates Transcytosis of Nanogranules across Epithelium by Triggering Polarity-Associated Transport Flow and Positive Cellular Feedback Loop. ACS Nano, 2019, 13, 5058-5076.	14.6	50

#	Article	IF	CITATIONS
37	Peptide–Drug Conjugate-Based Nanocombination Actualizes Breast Cancer Treatment by Maytansinoid and Photothermia with the Assistance of Fluorescent and Photoacoustic Images. Nano Letters, 2019, 19, 3229-3237.	9.1	40
38	Quick-Responsive Polymer-Based Thermosensitive Liposomes for Controlled Doxorubicin Release and Chemotherapy. ACS Biomaterials Science and Engineering, 2019, 5, 2316-2329.	5.2	19
39	<p>cRGDfK-Grafted Small-Size Quercetin Micelles For Enhancing Therapy Efficacy Of Active Ingredient From The Chinese Medicinal Herb</p> . International Journal of Nanomedicine, 2019, Volume 14, 9173-9184.	6.7	10
40	The appliances and prospects of aurum nanomaterials in biodiagnostics, imaging, drug delivery and combination therapy. Asian Journal of Pharmaceutical Sciences, 2019, 14, 349-364.	9.1	8
41	Preparation and in vivo pharmacokinetics of rhGH-loaded PLGA microspheres. Pharmaceutical Development and Technology, 2019, 24, 395-401.	2.4	6
42	Prussian blue nanosphere-embedded in situ hydrogel for photothermal therapy by peritumoral administration. Acta Pharmaceutica Sinica B, 2019, 9, 604-614.	12.0	31
43	pH-Sensitive morphological transitions in polymeric tadpole assemblies for programmed tumor therapy. Journal of Controlled Release, 2019, 293, 1-9.	9.9	18
44	\hat{l}_{\pm} -Conotoxin ImI-modified polymeric micelles as potential nanocarriers for targeted docetaxel delivery to \hat{l}_{\pm} 7-nAChR overexpressed non-small cell lung cancer. Drug Delivery, 2018, 25, 493-503.	5.7	28
45	Intestinal Mucin Induces More Endocytosis but Less Transcytosis of Nanoparticles across Enterocytes by Triggering Nanoclustering and Strengthening the Retrograde Pathway. ACS Applied Materials & Samp; Interfaces, 2018, 10, 11443-11456.	8.0	52
46	The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles. Journal of Controlled Release, 2018, 279, 136-146.	9.9	45
47	A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers. Journal of Controlled Release, 2018, 275, 129-141.	9.9	32
48	Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice. Scientific Reports, 2018, 8, 726.	3.3	50
49	Development and validation of an LCâ€MS/MS method for the determination of a novel thienoquinolin urea transporter inhibitor PUâ€48 in rat plasma and its application to a pharmacokinetic study. Biomedical Chromatography, 2018, 32, e4157.	1.7	4
50	Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes. Drug Delivery, 2018, 25, 112-121.	5.7	12
51	Effects of surface modification and size on oral drug delivery of mesoporous silica formulation. Journal of Colloid and Interface Science, 2018, 513, 736-747.	9.4	50
52	Effects of crystalline state and self-nanoemulsifying drug delivery system (SNEDDS) on oral bioavailability of the novel anti-HIV compound 6-benzyl-1-benzyloxymethyl-5-iodouracil in rats. Drug Development and Industrial Pharmacy, 2018, 44, 329-337.	2.0	3
53	The function and mechanism of preactivated thiomers in triggering epithelial tight junctions opening. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 188-199.	4.3	28
54	Receptor mediated transcytosis in biological barrier: The influence of receptor character and their ligand density on the transmembrane pathway of active-targeting nanocarriers. Biomaterials, 2018, 180, 78-90.	11.4	52

#	Article	IF	Citations
55	Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft. Drug Delivery, 2018, 25, 1495-1503.	5.7	54
56	The Improved Delivery to Breast Cancer Based on a Novel Nanocarrier Modified with Highâ€Affinity Peptides Discovered by Phage Display. Advanced Healthcare Materials, 2018, 7, e1800269.	7.6	7
57	Rho GTPases in A549 and Caco-2 cells dominating the endocytic pathways of nanocarbons with different morphologies. International Journal of Nanomedicine, 2018, Volume 13, 4391-4404.	6.7	13
58	Pharmacokinetics, Tissue Distribution and Excretion of a Novel Diuretic (PU-48) in Rats. Pharmaceutics, 2018, 10, 124.	4.5	8
59	Improved Cell Transfection of siRNA by pH-Responsive Nanomicelles Self-Assembled with mPEG- <i>b</i> -PHis- <i>b</i> -PEI Copolymers. ACS Applied Materials & The faces, 2018, 10, 21847-21860.	8.0	19
60	Single-walled carbon-nanohorns improve biocompatibility over nanotubes by triggering less protein-initiated pyroptosis and apoptosis in macrophages. Nature Communications, 2018, 9, 2393.	12.8	93
61	Transmembrane Pathways and Mechanisms of Rod-like Paclitaxel Nanocrystals through MDCK Polarized Monolayer. ACS Applied Materials & Samp; Interfaces, 2017, 9, 5803-5816.	8.0	33
62	Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone. Journal of Controlled Release, 2017, 249, 84-93.	9.9	37
63	Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix. Drug Delivery, 2017, 24, 270-277.	5.7	21
64	Combination antitumor therapy with targeted dual-nanomedicines. Advanced Drug Delivery Reviews, 2017, 115, 23-45.	13.7	111
65	Alphaâ€Tocopheryl Succinateâ€Conjugated G5 PAMAM Dendrimer Enables Effective Inhibition of Ulcerative Colitis. Advanced Healthcare Materials, 2017, 6, 1700276.	7.6	27
66	Anisotropy in Shape and Ligandâ€Conjugation of Hybrid Nanoparticulates Manipulates the Mode of Bio–Nano Interaction and Its Outcome. Advanced Functional Materials, 2017, 27, 1700406.	14.9	16
67	Biosafety study and mechanism comparison on two types of silica with different nanostructures. Toxicology Research, 2017, 6, 487-498.	2.1	3
68	Diverse Applications of Nanomedicine. ACS Nano, 2017, 11, 2313-2381.	14.6	976
69	Increased cellular uptake of peptide-modified PEGylated gold nanoparticles. Biochemical and Biophysical Research Communications, 2017, 494, 339-345.	2.1	25
70	Thermosensitive Hydrogel Containing Doxycycline Exerts Inhibitory Effects on Abdominal Aortic Aneurysm Induced By Pancreatic Elastase in Mice. Advanced Healthcare Materials, 2017, 6, 1700671.	7.6	6
71	The use of hydrophobic penetrating peptide cyclosporin A to deliver proapoptotic peptide: a possibly better choice than positively charged TAT. Journal of Controlled Release, 2017, 259, e133.	9.9	0
72	The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT. Journal of Controlled Release, 2017, 261, 174-186.	9.9	13

#	Article	IF	CITATIONS
73	Modulating Drug Release Rate from Partially Silica-Coated Bicellar Nanodisc by Incorporating PEGylated Phospholipid. Bioconjugate Chemistry, 2017, 28, 53-63.	3.6	22
74	The impact of receptor recycling on the exocytosis of $\hat{l}\pm\nu\hat{l}^23$ integrin targeted gold nanoparticles. Oncotarget, 2017, 8, 38618-38630.	1.8	15
75	Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics, 2017, 7, 538-558.	10.0	260
76	A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both $\hat{l}\pm v\hat{l}^2$ 3 Targeting and Reduction-Triggered Release for Maytansinoid. Theranostics, 2017, 7, 3306-3318.	10.0	22
77	The interactions of single-wall carbon nanohorns with polar epithelium. International Journal of Nanomedicine, 2017, Volume 12, 4177-4194.	6.7	11
78	A smart tumor targeting peptide–drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells. Drug Delivery, 2016, 23, 1-13.	5.7	38
79	The Effect of Hydrophilic and Hydrophobic Structure of Amphiphilic Polymeric Micelles on Their Transportation in Rats. Current Drug Delivery, 2016, 13, 105-110.	1.6	6
80	Novel Biological Functions of ZIFâ€NP as a Delivery Vehicle: High Pulmonary Accumulation, Favorable Biocompatibility, and Improved Therapeutic Outcome. Advanced Functional Materials, 2016, 26, 2715-2727.	14.9	128
81	Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1899-1907.	3.3	12
82	The Use of a Hydrophobic Binding Peptide Modified Lipid Nanocarrier Improving Tumor Distribution and Antitumor Efficacy. Journal of Biomedical Nanotechnology, 2016, 12, 1183-1198.	1.1	4
83	A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 387-397.	3.3	22
84	Dynamic bio-adhesion of polymer nanoparticles on MDCK epithelial cells and its impact on bio-membranes, endocytosis and paracytosis. Nanoscale, 2016, 8, 6129-6145.	5.6	8
85	Hybrid bicelles as a pH-sensitive nanocarrier for hydrophobic drug delivery. RSC Advances, 2016, 6, 79811-79821.	3.6	29
86	Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. Journal of Controlled Release, 2016, 241, 68-80.	9.9	114
87	Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2449-2458.	3.3	16
88	The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model. Journal of Controlled Release, 2016, 238, 186-196.	9.9	16
89	A comparative investigation between paclitaxel nanoparticle- and nanocrystal-loaded thermosensitive PECT hydrogels for peri-tumoural administration. Nanoscale, 2016, 8, 18782-18791.	5. 6	22
90	Systemic delivery of siRNA by hyaluronan-functionalized calcium phosphate nanoparticles for tumor-targeted therapy. Nanoscale, 2016, 8, 13033-13044.	5 . 6	59

#	Article	IF	Citations
91	Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats. Archives of Pharmacal Research, 2016, 39, 970-977.	6.3	5
92	Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug–Drug Conjugate with High Drug Loading and Antitumor Efficacy. Molecular Pharmaceutics, 2016, 13, 190-201.	4.6	99
93	Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery. Biomaterials, 2016, 80, 134-145.	11.4	33
94	A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 131-141.	3.3	68
95	Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis. Nanoscale, 2015, 7, 10790-10800.	5.6	78
96	G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol. Journal of Controlled Release, 2015, 210, 160-168.	9.9	41
97	Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers. International Journal of Pharmaceutics, 2015, 493, 380-389.	5.2	26
98	Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. Journal of Drug Targeting, 2015, 23, 67-78.	4.4	7
99	The use of \hat{l}_{\pm} -conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to \hat{l}_{\pm} 7 nAChR-overexpressing breast cancer. Biomaterials, 2015, 42, 52-65.	11.4	44
100	A comparative study of thermo-sensitive hydrogels with water-insoluble paclitaxel in molecule, nanocrystal and microcrystal dispersions. Nanoscale, 2015, 7, 14838-14847.	5.6	34
101	Bionano Interactions of MCF-7 Breast Tumor Cells with a Transferrin Receptor Targeted Nanoparticle. Molecular Pharmaceutics, 2015, 12, 1467-1476.	4.6	24
102	Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer. Journal of Controlled Release, 2015, 204, 11-19.	9.9	104
103	G5 PAMAM dendrimer versus liposome: A comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1141-1151.	3.3	32
104	Novel CD44 receptor targeting multifunctional "nano-eggs―based on double pH-sensitive nanoparticles for co-delivery of curcumin and paclitaxel to cancer cells and cancer stem cells. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	17
105	Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo. International Journal of Pharmaceutics, 2015, 495, 144-153.	5.2	7
106	A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. Journal of Controlled Release, 2015, 220, 189-200.	9.9	59
107	Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. International Journal of Pharmaceutics, 2015, 478, 718-725.	5.2	19
108	A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Drug Delivery, 2015, 22, 10-20.	5.7	39

#	Article	IF	Citations
109	Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches. Drug Delivery, 2014, 21, 588-594.	5.7	8
110	Dual pH-responsive and CD44 receptor targeted multifunctional nanoparticles for anticancer intracellular delivery. Journal of Nanoparticle Research, 2014, 16, 1.	1.9	5
111	The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3. Biomaterials, 2014, 35, 5908-5920.	11.4	40
112	Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet. International Journal of Pharmaceutics, 2014, 466, 276-285.	5.2	29
113	Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core–shell nanoparticles. Biomaterials, 2014, 35, 5028-5038.	11.4	129
114	Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials, 2014, 35, 2283-2294.	11.4	89
115	Pharmacokinetics and Treatment Efficacy of Camptothecin Nanocrystals on Lung Metastasis. Molecular Pharmaceutics, 2014, 11, 226-233.	4.6	29
116	Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin $\hat{l}\pm v\hat{l}^23$ clustering. Biomaterials, 2014, 35, 6106-6117.	11.4	97
117	Inhibition of Metastatic Tumor Growth and Metastasis via Targeting Metastatic Breast Cancer by Chlorotoxin-Modified Liposomes. Molecular Pharmaceutics, 2014, 11, 3233-3241.	4.6	56
118	Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. Journal of Controlled Release, 2014, 174, 161-170.	9.9	173
119	Novel Free-Paclitaxel-Loaded Redox-Responsive Nanoparticles Based on a Disulfide-Linked Poly(ethylene) Tj ETQq1 Activity in Vitro and in Vivo. Molecular Pharmaceutics, 2014, 11, 3656-3670.	1 0.78431 4.6	
120	Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclicÂoctapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer. Biomaterials, 2014, 35, 5347-5358.	11.4	90
121	Core-Shell type lipid/rPAA-Chol polymer hybrid nanoparticles for inÂvivo siRNA delivery. Biomaterials, 2014, 35, 2066-2078.	11.4	94
122	The development of site-specific drug delivery nanocarriers based on receptor mediation. Journal of Controlled Release, 2014, 193, 139-153.	9.9	88
123	Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: Preparation and comparison with other paclitaxel systems in vitro and in vivo. International Journal of Pharmaceutics, 2014, 471, 525-535.	5. 2	66
124	Gastro-floating tablets of cephalexin: Preparation and in vitro/in vivo evaluation. International Journal of Pharmaceutics, 2013, 452, 241-248.	5.2	45
125	Preparation and evaluation of a new releasable PEGylated tumor necrosis factor- \hat{l} ± (TNF- \hat{l} ±) conjugate for therapeutic application. Science China Life Sciences, 2013, 56, 51-58.	4.9	6
126	The effect of hydrophilic and hydrophobic structure of amphiphilic polymeric micelles on their transport in epithelial MDCK cells. Biomaterials, 2013, 34, 6284-6298.	11.4	37

#	Article	IF	CITATIONS
127	Combination of Targeted PDT and Anti-VEGF Therapy for Rat CNV by RGD-Modified Liposomal Photocyanine and Sorafenib., 2013, 54, 7983.		24
128	Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure. Particle and Fibre Toxicology, 2013, 10, 47.	6.2	53
129	In Vivo Studies of Octreotide-Modified N-Octyl-O, N-Carboxymethyl Chitosan Micelles Loaded with Doxorubicin for Tumor-Targeted Delivery. Journal of Pharmaceutical Sciences, 2013, 102, 126-135.	3.3	25
130	The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials, 2013, 34, 6082-6098.	11.4	193
131	The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials, 2013, 34, 2277-2288.	11.4	74
132	In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes. International Journal of Pharmaceutics, 2013, 445, 12-19.	5.2	86
133	The transport pathways of polymer nanoparticles in MDCK epithelial cells. Biomaterials, 2013, 34, 4309-4326.	11.4	97
134	Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials, 2013, 34, 794-806.	11.4	136
135	A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials, 2013, 34, 756-764.	11.4	44
136	Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials, 2013, 34, 1102-1114.	11.4	97
137	Efficient Simultaneous Tumor Targeting Delivery of All-Trans Retinoid Acid and Paclitaxel Based on Hyaluronic Acid-Based Multifunctional Nanocarrier. Molecular Pharmaceutics, 2013, 10, 1080-1091.	4.6	81
138	The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. International Journal of Nanomedicine, 2013, 8, 2473.	6.7	43
139	<i>In vitro</i> and <i>in vivo</i> studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Development and Industrial Pharmacy, 2012, 38, 1371-1380.	2.0	26
140	Peptide PHSCNK as an integrin $\hat{i}\pm5\hat{i}^21$ antagonist targets stealth liposomes to integrin-overexpressing melanoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1152-1161.	3.3	33
141	The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials, 2012, 33, 8451-8460.	11.4	105
142	A Cremophor-Free Self-Microemulsified Delivery System for Intravenous Injection of Teniposide: Evaluation In Vitro and In Vivo. AAPS PharmSciTech, 2012, 13, 846-852.	3.3	16
143	Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharmaceutical Research, 2012, 29, 2902-2911.	3.5	47
144	Successfully tailoring the pore size of mesoporous silica nanoparticles: Exploitation of delivery systems for poorly water-soluble drugs. International Journal of Pharmaceutics, 2012, 439, 81-91.	5.2	73

#	Article	IF	Citations
145	LyP-1 Modification To Enhance Delivery of Artemisinin or Fluorescent Probe Loaded Polymeric Micelles to Highly Metastatic Tumor and Its Lymphatics. Molecular Pharmaceutics, 2012, 9, 2646-2657.	4.6	57
146	Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson's disease in the MPTP-induced mice model. Journal of Drug Targeting, 2012, 20, 67-75.	4.4	66
147	Dual-functional liposomes based on pH-responsive cell-penetrating peptide andÂhyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials, 2012, 33, 9246-9258.	11.4	322
148	Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 401-409.	4.3	56
149	pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 219-229.	4.3	150
150	A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1. International Journal of Nanomedicine, 2012, 7, 4983.	6.7	11
151	EphA2 Targeted Doxorubicin Stealth Liposomes as a Therapy System for Choroidal Neovascularization in Rats., 2012, 53, 7348.		34
152	A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel to the Tumors with Overexpression of Somatostatin Receptors. Molecular Pharmaceutics, 2012, 9, 1175-1188.	4.6	40
153	The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials, 2012, 33, 679-691.	11.4	182
154	The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials, 2012, 33, 2508-2520.	11.4	100
155	Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system. Biomaterials, 2012, 33, 5431-5440.	11.4	71
156	Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials, 2012, 33, 6393-6407.	11.4	95
157	Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials, 2012, 33, 6793-6807.	11.4	115
158	Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 81-92.	3.3	59
159	Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. Journal of Controlled Release, 2012, 158, 413-423.	9.9	78
160	Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. Journal of Controlled Release, 2012, 160, 618-629.	9.9	90
161	Octreotide-Modified N-Octyl-O, N-Carboxymethyl Chitosan Micelles as Potential Carriers for Targeted Antitumor Drug Delivery. Journal of Pharmaceutical Sciences, 2012, 101, 627-640.	3.3	31
162	Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation <i>in vitro</i> and <i>in vivo</i> . Journal of Microencapsulation, 2011, 28, 528-536.	2.8	43

#	Article	IF	CITATIONS
163	A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 126-134.	4.3	54
164	Galactose-Decorated pH-Responsive Nanogels for Hepatoma-Targeted Delivery of Oridonin. Biomacromolecules, 2011, 12, 4335-4343.	5.4	120
165	The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nature Nanotechnology, 2011, 6, 385-391.	31.5	637
166	Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. Journal of Controlled Release, 2011, 149, 299-306.	9.9	70
167	Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. Journal of Controlled Release, 2011, 152, 402-410.	9.9	105
168	Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. International Journal of Pharmaceutics, 2011, 419, 339-346.	5.2	89
169	Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Biomaterials, 2011, 32, 9444-9456.	11.4	150
170	Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature. Journal of Drug Targeting, 2011, 19, 25-36.	4.4	19
171	Octreotide-Modified Polymeric Micelles as Potential Carriers for Targeted Docetaxel Delivery to Somatostatin Receptor Overexpressing Tumor Cells. Pharmaceutical Research, 2011, 28, 1167-1178.	3.5	39
172	Comprehensive studies on the interactions between chitosan nanoparticles and some live cells. Journal of Nanoparticle Research, 2011, 13, 4765-4776.	1.9	10
173	Preparation and antitumor study of camptothecin nanocrystals. International Journal of Pharmaceutics, 2011, 415, 293-300.	5.2	124
174	Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF- \hat{l}_{\pm}) against murine fibrosarcoma. Science China Life Sciences, 2011, 54, 128-138.	4.9	7
175	The antiangiogenic efficacy of NGR-modified PEG–DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. Journal of Drug Targeting, 2011, 19, 382-390.	4.4	49
176	The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats. Journal of Pharmacy and Pharmacology, 2010, 60, 99-105.	2.4	32
177	A Novel Octreotide Modified Lipid Vesicle Improved the Anticancer Efficacy of Doxorubicin in Somatostatin Receptor 2 Positive Tumor Models. Molecular Pharmaceutics, 2010, 7, 1159-1168.	4.6	93
178	Targeted Polymeric Micelle System for Delivery of Combretastatin A4 to Tumor Vasculature In Vitro. Pharmaceutical Research, 2010, 27, 1861-1868.	3.5	33
179	Analysis of cyclosporine A and its metabolites in rat urine and feces by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1153-1162.	2.3	19
180	Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids and Surfaces B: Biointerfaces, 2010, 80, 213-218.	5.0	109

#	Article	IF	CITATIONS
181	Two modelling data analytical methods applied to optimise the preparation of norcantharidin chitosan nanoparticles. Journal of Experimental Nanoscience, 2010, 5, 271-284.	2.4	8
182	Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion and transition of Rhodamine 6G in the gut of rats. Journal of Microencapsulation, 2010, 27, 205-217.	2.8	8
183	Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 467-473.	4.3	127
184	Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 170-178.	4.3	146
185	PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. Journal of Drug Targeting, 2010, 18, 254-263.	4.4	29
186	Targeted Treatment of Choroidal Neovascularization Using Integrin-Mediated Sterically Stabilized Liposomes Loaded With Combretastatin A4. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 195-200.	1.4	17
187	A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. Journal of Controlled Release, 2009, 135, 175-182.	9.9	124
188	NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. Journal of Controlled Release, 2009, 139, 56-62.	9.9	79
189	Dual-Targeting Topotecan Liposomes Modified with Tamoxifen and Wheat Germ Agglutinin Significantly Improve Drug Transport across the Bloodâ 'Brain Barrier and Survival of Brain Tumor-Bearing Animals. Molecular Pharmaceutics, 2009, 6, 905-917.	4.6	139
190	RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. Journal of Drug Targeting, 2009, 17, 459-467.	4.4	42
191	RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. Journal of Drug Targeting, 2009, 17, 10-18.	4.4	83
192	Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes. Journal of Controlled Release, 2008, 128, 113-119.	9.9	18
193	Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. Journal of Controlled Release, 2008, 129, 41-48.	9.9	70
194	A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. Journal of Controlled Release, 2008, 129, 18-25.	9.9	112
195	Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 899-907.	4.3	65
196	Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats. International Journal of Pharmaceutics, 2007, 329, 182-191.	5.2	37
197	Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization. Journal of Controlled Release, 2007, 117, 387-395.	9.9	164
198	Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabetic rats. Journal of Bone and Mineral Metabolism, 2007, 25, 293-301.	2.7	20

#	Article	IF	CITATIONS
199	Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid. International Journal of Pharmaceutics, 2006, 322, 146-153.	5.2	7
200	Preparation and Characterization of Insulin Nanoparticles Employing Chitosan and Poly(methylmethacrylate/methylmethacrylic acid) Copolymer. Journal of Nanoscience and Nanotechnology, 2006, 6, 2874-2886.	0.9	29
201	Thymopentin-Loaded pH-Sensitive Chitosan Nanoparticles for Oral Administration: Preparation, Characterization, and Pharmacodynamics. Journal of Nanoscience and Nanotechnology, 2006, 6, 2936-2944.	0.9	14
202	Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. Journal of Inorganic Biochemistry, 2005, 99, 1064-1075.	3.5	18
203	Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo. Acta Pharmacologica Sinica, 2005, 26, 1402-1408.	6.1	26
204	Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. Journal of Controlled Release, 2005, 107, 262-275.	9.9	192
205	Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: In vitro and in vivo. Journal of Pharmaceutical Sciences, 2005, 94, 1782-1793.	3.3	120
206	Frosted Branch Angiitis Secondary to Macular Choroidal Neovascularization in a Chinese Woman. Japanese Journal of Ophthalmology, 2005, 49, 228-230.	1.9	3
207	Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo. Pharmaceutical Research, 2005, 22, 933-939.	3.5	69
208	Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes. Peptides, 2005, 26, 423-430.	2.4	9
209	Gastrointestinal Absorption of Recombinant Hirudin-2 in Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 774-779.	2.5	9
210	pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. International Journal of Pharmaceutics, 2004, 280, 229-240.	5.2	148
211	Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. International Journal of Pharmaceutics, 2004, 281, 11-23.	5.2	97
212	A Pegylated Liposomal Platform: Pharmacokinetics, Pharmacodynamics, and Toxicity in Mice Using Doxorubicin as a Model Drug. Journal of Pharmacological Sciences, 2004, 95, 381-389.	2.5	61
213	Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. Journal of Controlled Release, 2004, 97, 421-429.	9.9	39
214	Phospholipid Deformable Vesicles for Buccal Delivery of Insulin Chemical and Pharmaceutical Bulletin, 2002, 50, 749-753.	1.3	58
215	Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations. International Journal of Pharmaceutics, 1999, 192, 115-121.	5.2	50